KLK3 and benign prostatic hyperplasia: Starting from the analysis of plasma samples collected before diagnostic biopsy from nearly 400 men, we previously uncovered a possible role of ceramides in discriminating PCa from benign prostatic hyperplasia when PSA was in the so-called “grey zone”, with 40% reduction of PSA false positives [3].